SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 143 filers reported holding SAGE THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,663,443 | +172.0% | 129,419 | +521.5% | 0.02% | +162.5% |
| Q2 2023 | $979,097 | +72.6% | 20,823 | +40.0% | 0.01% | +60.0% |
| Q4 2022 | $567,218 | +57.6% | 14,872 | +61.6% | 0.01% | +66.7% |
| Q3 2022 | $360,000 | -34.8% | 9,204 | -44.8% | 0.00% | -40.0% |
| Q1 2022 | $552,000 | -51.9% | 16,680 | +8.8% | 0.01% | -64.3% |
| Q1 2021 | $1,147,000 | -31.2% | 15,333 | -61.8% | 0.01% | -36.4% |
| Q2 2020 | $1,668,000 | +658.2% | 40,100 | +422.9% | 0.02% | +57.1% |
| Q1 2020 | $220,000 | -14.4% | 7,669 | +115.5% | 0.01% | +133.3% |
| Q4 2019 | $257,000 | -88.8% | 3,558 | -78.3% | 0.01% | -91.2% |
| Q3 2019 | $2,300,000 | +83.0% | 16,400 | +84.3% | 0.07% | +21.4% |
| Q3 2018 | $1,257,000 | +83.8% | 8,900 | +3.7% | 0.06% | -21.1% |
| Q2 2017 | $684,000 | -51.4% | 8,586 | -71.9% | 0.07% | -70.3% |
| Q3 2016 | $1,408,000 | +367.8% | 30,567 | +205.7% | 0.24% | +256.7% |
| Q2 2016 | $301,000 | -17.8% | 10,000 | -12.4% | 0.07% | -55.0% |
| Q1 2016 | $366,000 | – | 11,419 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |